

Laser Treatment of Scars and Keloids

Patrick Brown, MD; Mary E. Miller, MD; Justin Bandino, MD; Chad Hivnor, MD

The use of laser technology for the treatment of existing surgical scars as well as the minimization of new postoperative scars has gained considerable attention from the dermatologic and plastic surgery communities in recent years. We discuss the principles of scar treatment with both ablative and nonablative lasers, including the expanded role of fractionated technologies. We also review the evidence supporting the applicability of commonly encountered laser technologies in treating various scar types to provide busy practitioners with a resource that will facilitate the utilization of available lasers in the clinical setting. Finally, we discuss combination laser therapy, which we feel is the next frontier in laser scar treatment and prevention.

Cosmet Dermatol. 2012;25:318-325.

Scarring remains an inevitable effect of the wounding process. Scars may cause notable psychosocial morbidity secondary to poor cosmesis as well as functional impairment in the case of hypertrophic scars and keloids. Techniques to minimize scar burden have been employed since ancient times, but historically the treatment and prevention of scarring has been disappointing. Exciting new research on the minimization of postoperative and traumatic scarring currently is being conducted, and the use of existing laser technologies has proven beneficial in the treatment of established scars.

Scars can be broadly classified as hypertrophic scars, keloids, atrophic scars, and acne scars. Prior reviews of laser scar revision techniques have been organized according to the type of scar.¹ This review presents an overview of laser principles as they pertain to the treatment of scars followed by a synopsis of scar treatment organized by laser type to facilitate the busy practitioner's utilization of available resources.

PRINCIPLES OF LASER SCAR TREATMENT

Laser scar treatment is dependent on Anderson and Parrish's² theory of selective photothermolysis. By keeping the pulse width for a given laser shorter than the thermal relaxation time for its intended chromophore, photothermal effects are largely limited to the intended chromophore, thus reducing nonspecific or bulk heating.

Ablative laser systems such as the CO₂ and erbium:YAG (Er:YAG) lasers target water, thus promoting the vaporization of tissue. Continuous-wave ablative lasers commonly were utilized in the 1980s and 1990s; however, despite their effectiveness, these devices have fallen out of favor because of the high risk for adverse effects including scarring. To better control nonspecific heating, short-pulsed ablative lasers with high-peak power, which had the

From San Antonio Uniformed Services Health Education Consortium, Texas.

The authors report no conflicts of interest in relation to this article. The views expressed in this article are those of the authors and do not reflect the official policy or position of the US Army, the US Department of Defense, or the US Government.

Correspondence: Chad Hivnor, MD, Department of Dermatology, Wilford Hall Ambulatory Surgical Center, 2200 Bergquist Dr, Lackland AFB, TX 78236 (chad.hivnor@us.af.mil).

advantage of reliable ablation depth with decreased risk for scarring, were created, but prolonged recovery times following resurfacing procedures remained unattractive.³ Subsequently, short-pulsed ablative energy was pixilated, thus creating deep columns of ablated tissue, also known as microthermal zones, between intervening sections of native dermis in a technique called fractional photothermolysis. Repopulation of microthermal zones by adjacent intact skin resulted in notably reduced recovery time at the expense of decreased single treatment effectiveness.⁴

Nonablative laser systems can be classified into 2 main groups: visible-light lasers (eg, pulsed dye laser [PDL] and 532-nm systems) and infrared lasers that include wavelengths designed to target the dermis and promote neocollagenesis.³ Although they technically are not lasers, intense pulsed light (IPL) devices commonly are included in discussions of visible-light lasers because of their effective spectrum. The primary scar treatment effects of the visible-light group often are considered secondary to their vasodestructive properties, but PDL and IPL have been shown to variably initiate neocollagenesis in atrophic and photodamaged skin through unspecified mechanisms,^{5,6} albeit to a lesser degree than midinfrared wavelengths.⁷ Similar to ablative devices, midinfrared spectrum lasers often are fractionated, which increases the depth of collagen-stimulating thermal injury within microthermal zones, while the untreated adjacent epidermis minimizes healing time.⁸

VISIBLE LIGHT-SPECTRUM NONABLATIVE LASERS

Intense Pulsed Light

Controlled trials with objective metrics to assess the efficacy of IPL in scar treatment generally are lacking.^{9,10} In a study of 109 patients with hypertrophic scars resulting from surgical incisions, trauma, acne, burns, or keloids, 92.5% of patients experienced subjective improvement in height, erythema, and hardness of their scars compared with baseline after an average of 8 IPL treatments.¹¹ In a split-scar study of hypertrophic scars of 6 to 8 weeks' duration from breast reduction or abdominoplasty procedures, treatment with both IPL and long-pulse PDL (1.5 milliseconds) resulted in similar subjective improvement¹²; however, without a control group, it is difficult to ascertain how much of the observed improvement in both groups resulted from maturation of these relatively young scars.

Frequency-Doubled Nd:YAG and Potassium Titanyl Phosphate Lasers (532 nm)

One controlled, split-scar study of 6 patients with pigmented hypertrophic scars reported similar

improvement (36%–38%) on the Vancouver General Hospital burn scar assessment scale following treatment with the 585-nm flashlamp-pumped PDL (0.45 milliseconds) and Q-switched frequency-doubled Nd:YAG lasers, whereas the variable-pulsed mode on the same Nd:YAG laser (10 milliseconds) showed no benefit and was similar to the control group (untreated). The authors concluded that improvement of hyperpigmentation was responsible for most of the clinical effect.¹³

There is a paucity of data on the use of potassium titanyl phosphate (KTP) lasers in the treatment and prevention of scarring. Vaccaro et al¹⁴ treated half of an established hypertrophic postthyroidectomy scar with the KTP laser and found substantial improvement in elasticity and visual appearance versus the untreated portion of the scar. In a study of 28 Asian patients with postthyroidectomy linear anterior neck incisions, Yun et al¹⁵ prophylactically treated 20 patients using a 532-nm KTP laser for 2 treatments administered at 2-week intervals; the remaining 8 patients served as controls. Following the treatment period, the authors reported lower Vancouver scar scale and global assessment scores and higher patient satisfaction in the treatment group versus the control group.¹⁵

Pulsed Dye Laser

The PDL remains the workhorse for treatment of hypertrophic (Figure 1) and keloidal scars. In a 1994 report, Alster¹⁶ used a 585-nm, flashlamp-pumped PDL to treat established hypertrophic surgical scars, reporting a 57% improvement in scar texture after 1 treatment and an 83% improvement after a second treatment. It was the first report in which the PDL laser was found to not only reduce erythema within scars but also to presumably



Figure 1. A hypertrophic scar following carpal tunnel surgery photographed after 2 pulsed dye laser treatments. Note the variable response to treatment, which was based on scar thickness. The thicker areas of this scar eventually flattened with adjuvant intralesional steroid treatment.

redirect haphazard collagenesis as seen by reduction in scar thickness.¹⁶ Alster and McMeekin¹⁷ subsequently demonstrated equally impressive results in a split-face study of hypertrophic and/or erythematous acne scars using the same device. A 2011 systemic review of controlled trials found the most evidence for the 585-nm PDL in the treatment of hypertrophic scars of various etiologies.¹⁰ Despite its more robust evidence base, the 585-nm PDL showed lower efficacy than the less often employed 595-nm PDL in the treatment of established (>6 months' duration) hypertrophic scars. The reviewers concluded there is little evidence to support lasers other than the PDL in the treatment of established hypertrophic scars.¹⁰

In 1999, McCraw et al¹⁸ initially demonstrated decreased frequency of hypertrophic scar formation and improved cosmetic outcome in traumatic and surgical wounds when sequential laser treatments were performed early after wound formation, thus suggesting the 585-nm PDL can be used to prevent aberrant scar formation. Attempts to reproduce these results using a single pass of the PDL laser upon suture removal were unsuccessful.¹⁹ McCraw et al's¹⁸ findings were eventually confirmed by Nouri et al²⁰ who noted improvement of every parameter in the Vancouver scar scale after 3 monthly 585-nm PDL treatments initiated on suture removal. Furthermore, they were able to achieve similar benefits with either a 0.45- or 1.5-millisecond pulse width²⁰; however, in the treatment of established hypertrophic scars, shorter pulse widths (eg, 0.45 milliseconds) are more efficacious than longer pulse widths.²¹ The response to varying pulse widths in early wounds may be explained by nonspecific thermal effects on dermal collagen via signaling molecules such as heat shock proteins, whereas the dependency on short pulse widths for established hypertrophic scars may indicate that the benefits are derived primarily through the specific angi destructive properties of this laser, which is likely an oversimplified explanation for the complex interaction between specific wavelengths of laser energy and the early wound. Nouri et al²² also reported improvement in scar height with the 585-nm PDL that was not seen with the 595-nm PDL employed on suture removal, despite similar improvements in vascularity and pliability for these 2 wavelengths.

Parrett and Donelan²³ reviewed 6 published reports of PDL used in the treatment of hypertrophic scars from thermal burns. They concluded that the PDL leads to flattening of hypertrophic scars; improved texture and pliability; and decreased erythema, pain, and pruritus, usually after only 2 to 3 treatments. Moreover, they found no evidence of recurrent or worsening scars over the 4-week to 6-month follow-up periods in the reviewed studies.²³ However, rapid recurrence of keloidal scarring has been reported following treatment with the PDL,²⁴ suggesting

that data from studies on hypertrophic scars cannot necessarily be extrapolated to keloids.

Diode Laser (810 nm)

The majority of research conducted using the 810-nm diode laser involves the laser-assisted skin healing (LASH) technique. Capon et al²⁵ found significant subjective improvement in a split abdominoplasty scar study using LASH technology at the time of skin closure; patients treated with high-dose (80–130 mJ/cm²) laser energy demonstrated a 38.1% reduction in scar height with profilometry at 12 months following treatment ($P=.027$) as opposed to an insignificant difference versus control with lower-energy treatments.²⁵ Capon et al²⁶ also reported success using LASH technology in combination with silicone gel sheeting immediately following reexcision of existing hypertrophic scars. Although the mechanism of action for prophylactic laser treatment remains unknown, we agree with previously published studies that cite the modification of transforming growth factor β expression via induction of heat shock proteins (specifically heat shock protein 70) as a plausible etiology.²⁷

INFRARED-SPECTRUM NONABLATIVE LASERS

Nd:YAG (1064 or 1320 nm) or Diode (1450 nm) Lasers

Infrared-spectrum nonablative lasers utilize wavelengths that selectively target water-containing tissues but provide concomitant surface cooling to prevent epidermal damage. Currently, fractionated systems are particularly popular. Treatment protocols commonly call for 3 to 4 treatments administered at 1-month intervals. Nonablative fractional laser systems have the advantage of minimal downtime with fewer side effects, especially in darker-skinned patients.

Several studies document the beneficial effects of the Nd:YAG laser in treating facial rhytides, but few address its effects on scarring. Friedman et al²⁸ used an optical profiler to show continued quantitative improvements in atrophic acne scarring 6 months after the fifth treatment with a Q-switched 1064-nm Nd:YAG laser. Treatments were well-tolerated aside from the development of pinpoint petechiae,²⁸ which previously was reported as a side effect of this device.²⁹ The 6-month improvement rate was 39.2%,²⁸ which may underestimate the potential of this laser; extended follow-up may be necessary. Treatment with the long-pulsed Nd:YAG laser also has demonstrated improvement in atrophic acne scarring in 11 of 12 patients following 5 treatments, which correlated with a statistically significant increase ($P<.05$) in collagen on biopsy.³⁰ The long-pulsed Nd:YAG laser also is well-tolerated and

has the distinct advantage of being safe and effective for use on darker skin types.³⁰

Although the majority of midinfrared lasers encountered in clinical practice today are fractionated, their unfractionated predecessors still are in use and are supported by data.³¹⁻³³ In a split-face study comparing long-pulsed 1320-nm Nd:YAG and 1450-nm diode lasers for the treatment of atrophic acne scars, Tanzi and Alster³¹ demonstrated improvement in blinded appraisal of digital photographs that peaked 6 months after a series of 3 treatments with each laser. Quantitative surface topography improvement also peaked at 6 months but still remained statistically significant ($P=.008$) at the 12-month follow-up when compared to baseline. Histologically, this peak in clinical benefit coincided with the cessation of neocollagenesis after 6 months. Although both devices demonstrated improvement, the 1450-nm diode laser showed a greater response for the parameters measured at each time point.³¹ These laser systems also may be considered safe for use in pigmented skin.^{33,34}

FRACTIONATED NONABLATIVE LASERS

Erbium:Glass (1540 and 1550 nm) and Nd:YAG (1440 nm) Lasers

Fractionated nonablative lasers were developed in the mid-2000s to address the need for more substantial clinical improvements than what was possible using long-pulsed midinfrared systems. Alster et al³⁵ initially reported the efficacy of fractionated nonablative resurfacing for atrophic acne scars in 2007, with a clinical improvement rate of 51% to 75% seen in 87% (20/23) of patients after 3 monthly treatments. Chrastil et al³⁶ reported similar results with 23 of 29 (79%) patients experiencing greater than 50% improvement after 2 to 6 monthly treatments without persistent adverse effects, even in darker skin types. A split-face study compared the efficacy of 1540-nm fractionated laser after 3 monthly treatments versus no treatment in 10 patients with atrophic acne scars; despite the small sample size, a statistically significant ($P=.03$) improvement in blinded on-site clinical evaluation was maintained 12 weeks following the final treatment.³⁷

Although most physicians still consider PDL to be the gold standard for treatment of erythematous and elevated scars, evidence suggests that nonablative fractionated resurfacing may play a role in the treatment of unsightly postsurgical scars. In a split-scar study of patients 2 months following Mohs micrographic surgery, Tierney et al³⁸ observed more significant improvement in overall scar appearance in the section that was treated with a fractionated 1550-nm laser compared with the section that was treated with 595-nm PDL ($P<.001$). A

smaller study by Niwa et al³⁹ found moderate improvement when comparing baseline and posttreatment photographs of 8 patients who received fractionated 1550-nm laser treatment to their entire surgical scar. In a randomized controlled trial, Haedersdal et al⁴⁰ found significant ($P=.0007$) improvement in the texture of mature burn scars 12 weeks following the completion of 3 treatments with a 1540-nm fractionated laser versus no treatment. Despite the relatively high incidence of adverse effects, patient satisfaction remained high.⁴⁰ Finally, Waibel and Beer⁴¹ reported drastic improvement in hypertrophic scarring with the use of a fractionated 1550-nm laser in a severely burned patient whose scars previously were refractory to intralesional steroids.

ABLATIVE LASERS (CONTINUOUS, PULSED, AND FRACTIONATED)

CO₂ Laser (10,600 nm)

CO₂ resurfacing came to the forefront of acne scar treatment with the advent of pulsed systems that were able to minimize thermal injury to uninvolved adjacent skin in the mid-1990s, thus reducing the risk for adverse effects. In the initial report of pulsed CO₂ lasers for the treatment of acne scarring, Alster and West⁴² demonstrated an 81.4% average clinical improvement in acne scars after only 1 treatment but noted hyperpigmentation lasting an average of 3 months in 36% of patients. In 2008, Chapas et al⁴³ described the use of a fractionated CO₂ resurfacing technique for the treatment of acne scars. The mean level of improvement after 2 to 3 monthly treatments (66.8%) was felt to be slightly less than that achieved using a single pass with the pulsed CO₂ predecessor, but the side-effect profile and healing times were more desirable than those associated with continuous or pulsed CO₂ lasers.⁴³ In 2012, Ong and Bashir⁴⁴ reviewed all 26 published reports of fractional ablative and nonablative acne scar resurfacing and found that although nonablative devices had a better side-effect profile, there was more potential for improvement with ablative (26%–83%) versus nonablative (26%–50%) fractionated lasers. Although the safety of both ablative and nonablative fractional devices in ethnic skin has been documented,⁴⁵ our experience has suggested that there is increased risk for temporary hyperpigmentation when using ablative wavelengths at more aggressive settings.

Although the vast majority of published reports for CO₂ laser systems involve the treatment of acne scars, there also is evidence to suggest utility in other forms of scarring (Figure 2). In a study of 15 patients with 22 non-atrophic acne scars, 3 treatments with the fractionated CO₂ laser led to a 38% mean reduction in scar volume and a 35.6% mean reduction in maximum scar depth at




Figure 2. A postthyroidectomy scar with malapproximation of the wound edges leading to a poor cosmetic outcome (A). Induration and pliability responded favorably to 3 treatments with a fractionated CO₂ laser (B), while the resulting hyperpigmentation responded to treatment with an alexandrite Q-switched laser (not pictured).

6 months. This degree of dermal rejuvenation was sufficient to create perceived improvements in texture, atrophy, and overall scar appearance by both investigators and patients at 6 months posttreatment.⁴⁶ Lee et al⁴⁷ reported subjective improvement in all 27 patients with striae distensae treated with a single pass of a fractionated CO₂ laser, noting that nonablative fractional systems approved for this indication usually require multiple treatments. However, when 3 treatments with the nonablative 1550-nm fractionated laser were compared head-to-head with 3 fractionated CO₂ treatments in a split-scar study for striae distensae, no significant difference between the 2 wavelengths was found.⁴⁸

CO₂ laser resurfacing also has come to the forefront of hypertrophic and/or burn scar treatment. Although continuous-wave and pulsed devices were often fraught with unpredictability and unacceptable downtime, a 2006 Iranian study of more than 300 patients receiving 10 weekly low-level laser treatments for burn scars using a scanning CO₂ system showed significant ($P < .001$) improvement to resolution for hypertrophic scars of 1 to 6 months' duration, whereas there was only moderate to limited effect in more mature scars.⁴⁹ More recently, several case reports have highlighted the potential of fractionated CO₂ in this patient population. Waibel and Beer⁵⁰ demonstrated drastic clinical improvement in a long-standing facial burn scar with a single treatment of a fractionated CO₂ laser, citing the potential role of heat shock proteins in skin remodeling. Cho et al⁵¹ demonstrated safety and efficacy of the fractionated CO₂ laser in the treatment of thermal burn scars in an Asian patient.

Despite the improved safety profile of newer fractionated CO₂ lasers, it is still possible to induce new hypertrophic scarring with these devices, and as such caution must be exercised.⁵²

Ablative laser resurfacing also is being used in the prevention of undesirable scarring postoperatively and following nonburn trauma. Early intervention with fractionated CO₂ 2 to 3 weeks postthyroidectomy has been suggested to improve the clinical appearance of hypertrophic scarring in at least 1 uncontrolled trial.⁵³ Jared Christophel et al⁵⁴ conducted a split-scar study comparing fractionated CO₂ to diamond fraise dermabrasion in postsurgical scars and found similar efficacy between the modalities but increased safety with CO₂. Treatment of the wound edge intraoperatively with either pulsed CO₂⁵⁵ or fractionated CO₂⁵⁶ has proven to benefit postoperative scar appearance.

Er:YAG Laser (2940 nm)

The water absorption coefficient for the Er:YAG laser is 16 times that of the CO₂ laser, which leads to less penetration depth per laser pass, less thermal injury, poor hemostasis, and reduced efficacy for facial resurfacing with short-pulsed Er:YAG.^{3,57} The limited penetration of Er:YAG has been overcome by newer devices that utilize increased pulse widths, thus allowing deeper thermal damage and increased effectiveness in the treatment of atrophic acne scarring.^{58,59} Although shallow boxcar and ice pick-type scars respond to any type of Er:YAG laser, longer pulse durations are required to stimulate the collagenesis that improves rolling and deep boxcar scars.⁶⁰ Not surprisingly, the side-effect profile of the long-pulse Er:YAG laser is similar to pulsed CO₂ resurfacing for acne scars.⁶¹

There is 1 randomized larger study assessing the utility of Er:YAG in the treatment of traumatic or surgical hypertrophic scars. The authors concluded that both the low-energy, short-pulsed Er:YAG laser and standard flashlamp PDL were superior to intralesional steroid injection, but they did not appear to find any significant difference between the 2 lasers.⁶² A large potential for bias has been noted in this study.¹⁰

COMBINATION THERAPY

CO₂ Laser and PDL

Some investigators have postulated that increased benefits can be achieved if combination laser therapy is utilized in the treatment of postsurgical or traumatic scars (Figure 3); to our knowledge, however, few studies exist. Pulsed dye laser therapy remains an excellent option for the erythematous component of established scars, but as previously mentioned, it also can improve



Figure 3. Complex traumatic scars respond best to a multiple laser approach. This road rash scar following a motorcycle accident responded well to treatment with a Q-switched laser to improve resultant hyperpigmentation/traumatic tattoos, a pulsed dye laser to improve erythema, and a fractionated ablative laser to improve surface texture.

other variables such as scar texture and height. Alster et al⁶³ compared the results of a pulsed CO₂ laser with and without simultaneous PDL treatment and found the combination therapy to be superior in the resurfacing of nonerythematous hypertrophic scars. Similar to Manuskiatti et al⁶⁴ who used multiple wavelengths to target specific chromophores in a single laser resurfacing session to repair photodamaged skin, we have found that the treatment and/or prevention of hypertrophic and otherwise unsightly postsurgical and traumatic scars can be improved by a multiple modality approach. As such, we currently are conducting a randomized controlled study to compare the effects of fractionated CO₂ laser therapy, PDL therapy, and a combined therapy using both devices in minimizing postsurgical scars (P.B. and C.H., unpublished data, 2012).

Intralesional Therapy

Intralesional steroid injections once were considered the standard therapy to which all scar reduction modalities were compared. Several studies that assess the efficacy of lasers for scar reduction include comparisons to intralesional steroids. Manuskiatti and Fitzpatrick⁶⁵ reported similarities in clinical improvement when comparing 585-nm PDL monotherapy, 5-fluorouracil monotherapy, intralesional steroid monotherapy, and intralesional steroid in combination with 5-fluorouracil; however, the authors noted more unwanted side effects in the corticosteroid treatment groups. There are fewer trials that assess combination laser and intralesional injection therapies. Asilian et al⁶⁶ found the combination of an intralesional steroid, 5-fluorouracil, and 585-nm PDL to be more

effective in treating keloids and hypertrophic scars than the intralesional steroid alone or in combination with 5-fluorouracil only.

FUTURE DIRECTIONS

Scar prevention and treatment have come to the forefront of dermatology within the last few years. Several recent review articles that address treatment modalities and the pathogenesis of wound healing hopefully will encourage continued research in this intriguing field.^{1,9,67,68} Combination therapies that warrant further investigation with prospective controlled studies include dermal fillers combined with fractionated CO₂ resurfacing for the treatment of acne scars, botulinum toxin combined with early fractionated CO₂ with and without PDL resurfacing, and laser resurfacing combined with a variety of wound dressings.

REFERENCES

1. Khatri K, Mahoney DL, McCartney MJ. Laser scar revision: a review. *J Cosmet Laser Ther.* 2011;13:54-62.
2. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. *Science.* 1983;220:524-527.
3. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. *J Am Acad Dermatol.* 2008;58:719-737; quiz 738-740.
4. Tierney EP, Kouba DJ, Hanke CW. Review of fractional photothermolysis: treatment indications and efficacy [published online ahead of print July 20, 2009]. *Dermatol Surg.* 2009;35:1445-1461.
5. Zelickson BD, Kilmer SL, Bernstein E, et al. Pulsed dye laser therapy for sun damaged skin. *Lasers Surg Med.* 1999;25:229-236.
6. Zelickson BD, Kist D. Effect of pulsed dye laser and intense pulsed light source on the dermal extracellular matrix remodeling [abstract]. *Lasers Surg Med.* 2000;(suppl 12):17.
7. Orringer JS, Voorhees JJ, Hamilton T, et al. Dermal matrix remodeling after nonablative laser therapy [published online ahead of print September 23, 2005]. *J Am Acad Dermatol.* 2005;53:775-782.
8. Laubach HJ, Tannous Z, Anderson RR, et al. Skin responses to fractional photothermolysis. *Lasers Surg Med.* 2006;38:142-149.
9. Tziotzios C, Profyris C, Sterling J. Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics part II. strategies to reduce scar formation after dermatologic procedures. *J Am Acad Dermatol.* 2012;66:13-24; quiz 25-26.
10. Vrijman C, van Drooge AM, Limpens CE, et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. *Br J Dermatol.* 2011;165:934-942.
11. Erol OO, Gurlek A, Agaoglu G, et al. Treatment of hypertrophic scars and keloids using intense pulsed light (IPL)[published online ahead of print June 17, 2008]. *Aesthetic Plast Surg.* 2008;32:902-909.
12. Bellew SG, Weiss MA, Weiss RA. Comparison of intense pulsed light to 595-nm long-pulsed pulsed dye laser for treatment of hypertrophic surgical scars: a pilot study. *J Drugs Dermatol.* 2005;4:448-452.
13. Bowes LE, Nouri K, Berman B, et al. Treatment of pigmented hypertrophic scars with the 585 nm pulsed dye laser and the 532 nm frequency-doubled Nd:YAG laser in the Q-switched

- and variable pulse modes: a comparative study. *Dermatol Surg.* 2002;28:714-719.
14. Vaccaro M, Borgia F, Guarneri B. Treatment of hypertrophic thyroidectomy scar using 532-nm potassium-titanyl-phosphate (KTP) laser. *Int J Dermatol.* 2009;48:1139-1141.
 15. Yun JS, Choi YJ, Kim WS, et al. Prevention of thyroidectomy scars in Asian adults using a 532-nm potassium titanyl phosphate laser [published online ahead of print August 24, 2011]. *Dermatol Surg.* 2011;37:1747-1753.
 16. Alster TS. Improvement of erythematous and hypertrophic scars by 585-nm flashlamp-pumped pulsed dye laser. *Ann Plast Surg.* 1994;32:186-190.
 17. Alster TS, McMeekin TO. Improvement of facial acne scars by the 585 nm flashlamp-pumped pulse dye laser. *J Am Acad Dermatol.* 1996;35:79-81.
 18. McCraw JB, McCraw JA, McMellin A, et al. Prevention of unfavorable scars using early pulse dye laser treatments: a preliminary report. *Ann Plast Surg.* 1999;42:7-14.
 19. Alam M, Pon K, Van Laborde S, et al. Clinical effect of a single pulsed dye laser treatment of fresh surgical scars: randomized controlled trial. *Dermatol Surg.* 2006;32:21-25.
 20. Nouri K, Elsaie ML, Vejjabhinanta V, et al. Comparison of the effects of short- and long-pulse durations when using a 585-nm pulsed dye laser in the treatment of new surgical scars [published online ahead of print August 7, 2009]. *Lasers Med Sci.* 2010;25:121-126.
 21. Manuskiatti W, Wanitphakdeedecha R, Fitzpatrick RE. Effect of pulse width of a 595-nm flashlamp-pumped pulsed dye laser on the treatment response of keloidal and hypertrophic sternotomy scars. *Dermatol Surg.* 2007;33:152-161.
 22. Nouri K, Rivas MP, Stevens M, et al. Comparison of the effectiveness of the pulsed dye laser 585 nm versus 595 nm in the treatment of new surgical scars [published online ahead of print July 2, 2009]. *Lasers Med Sci.* 2009;24:801-810.
 23. Parrett BM, Donelan MB. Pulsed dye laser in burn scars: current concepts and future directions [published online ahead of print December 21, 2009]. *Burns.* 2010;36:443-449.
 24. Shih PY, Chen HH, Chen CH, et al. Rapid recurrence of keloid after pulse dye laser treatment [published online ahead of print May 7, 2008]. *Dermatol Surg.* 2008;34:1124-1127.
 25. Capon A, Iarmarcovai G, Gonnelli D, et al. Scar prevention using laser-assisted skin healing (LASH) in plastic surgery [published online ahead of print January 28, 2010]. *Aesthetic Plast Surg.* 2010;34:438-446.
 26. Capon A, Iarmarcovai G, Mordon S. Laser-assisted skin healing (LASH) in hypertrophic scar revision. *J Cosmet Laser Ther.* 2009;11:220-223.
 27. Leclère FM, Mordon SR. Twenty-five years of active laser prevention of scars: what have we learned? *J Cosmet Laser Ther.* 2010;12:227-234.
 28. Friedman PM, Jih MH, Skover GR, et al. Treatment of atrophic facial acne scars with the 1064-nm Q-switched Nd:YAG laser: six-month follow-up study. *Arch Dermatol.* 2004;140:1337-1341.
 29. Goldberg DJ, Whitworth J. Laser skin resurfacing with the Q-switched Nd:YAG laser. *Dermatol Surg.* 1997;23:903-906; discussion 906-907.
 30. Keller R, Belda Júnior W, Valente NY, et al. Nonablative 1,064-nm Nd:YAG laser for treating atrophic facial acne scars: histologic and clinical analysis. *Dermatol Surg.* 2007;33:1470-1476.
 31. Tanzi EL, Alster TS. Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. *Dermatol Surg.* 2004;30(2, pt 1):152-157.
 32. Bellew SG, Lee C, Weiss MA, et al. Improvement of atrophic acne scars with a 1,320 nm Nd:YAG laser: retrospective study. *Dermatol Surg.* 2005;31(9, pt 2):1218-1221; discussion 1222.
 33. Chua SH, Ang P, Khoo LS, et al. Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. *Dermatol Surg.* 2004;30:1287-1291.
 34. Goldberg DJ. Nonablative laser surgery for pigmented skin. *Dermatol Surg.* 2005;31:1263-1267.
 35. Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. *Dermatol Surg.* 2007;33:295-299.
 36. Chrastil B, Glaich AS, Goldberg LH, et al. Second-generation 1,550-nm fractional photothermolysis for the treatment of acne scars. *Dermatol Surg.* 2008;34:1327-1332.
 37. Hedelund L, Moreau KE, Beyer DM, et al. Fractional nonablative 1,540-nm laser resurfacing of atrophic acne scars: a randomized controlled trial with blinded response evaluation [published online ahead of print June 17, 2010]. *Lasers Med Sci.* 2010;25:749-754.
 38. Tierney E, Mahmoud BH, Srivastava D, et al. Treatment of surgical scars with nonablative fractional laser versus pulsed dye laser: a randomized controlled trial [published online ahead of print February 23, 2009]. *Dermatol Surg.* 2009;35:1172-1180.
 39. Niwa ABM, Mello APF, Torezan LA, et al. Fractional photothermolysis for the treatment of hypertrophic scars: clinical experience of eight cases [published online ahead of print March 23, 2008]. *Dermatol Surg.* 2009;35:773-777; discussion 777-778.
 40. Haedersdal M, Moreau KE, Beyer DM, et al. Fractional nonablative 1540 nm laser resurfacing for thermal burn scars: a randomized controlled trial. *Lasers Surg Med.* 2009;41:189-195.
 41. Waibel J, Beer K. Fractional laser resurfacing for thermal burns. *J Drugs Dermatol.* 2008;7:59-61.
 42. Alster TS, West TB. Resurfacing of atrophic facial acne scars with high-energy pulsed carbon dioxide laser. *Dermatol Surg.* 1996;22:151-154; discussion 154-155.
 43. Chapas AM, Brightman L, Sukal S, et al. Successful treatment of acneiform scarring with CO₂ ablative fractional resurfacing. *Lasers Surg Med.* 2008;40:381-386.
 44. Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: a review [published online ahead of print May 8, 2012]. *Br J Dermatol.* 2012;166:1160-1169.
 45. Alajlan AM, Alsuwaidan SN. Acne scars in ethnic skin treated with both non-ablative fractional 1550 nm and ablative fractional CO₂ lasers: comparative retrospective analysis with recommended guidelines. *Lasers Surg Med.* 2011;43:787-791.
 46. Weiss ET, Chapas A, Brightman L, et al. Successful treatment of atrophic postoperative and traumatic scarring with carbon dioxide ablative fractional resurfacing: quantitative volumetric scar improvement. *Arch Dermatol.* 2010;146:133-140.
 47. Lee SE, Kim JH, Lee SJ, et al. Treatment of striae distensae using an ablative 10,600-nm carbon dioxide fractional laser: a retrospective review of 27 participants [published online ahead of print September 14, 2010]. *Dermatol Surg.* 2010;36:1683-1690.
 48. Yang YJ, Lee GY. Treatment of striae distensae with nonablative fractional laser versus ablative CO₂ fractional laser: a randomized controlled trial [published online ahead of print November 3, 2011]. *Ann Dermatol.* 2011;23:481-489.
 49. Ghalambor AA, Pipelzadeh MH. Low level CO₂ laser therapy in burn scars: which patients benefit most? *Pak J Med Sci.* 2006;22:158-161.
 50. Waibel J, Beer K. Ablative fractional laser resurfacing for the treatment of a third-degree burn. *J Drugs Dermatol.* 2009;8:294-297.

51. Cho SB, Lee SJ, Chung WS, et al. Treatment of burn scar using a carbon dioxide fractional laser. *J Drugs Dermatol*. 2010;9:173-175.
52. Lee SJ, Kim JH, Lee SE, et al. Hypertrophic scarring after burn scar treatment with a 10,600-nm carbon dioxide fractional laser [published online ahead of print June 2, 2011]. *Dermatol Surg*. 2011;37:1168-1172.
53. Jung JY, Jeong JJ, Roh HJ, et al. Early postoperative treatment of thyroidectomy scars using a fractional carbon dioxide laser [published online ahead of print January 27, 2011]. *Dermatol Surg*. 2011;37:217-223.
54. Jared Christophel J, Elm C, Endrizzi BT, et al. A randomized controlled trial of fractional laser therapy and dermabrasion for scar resurfacing [published online ahead of print January 23, 2012]. *Dermatol Surg*. doi:10.1111/j.1524-4725.2011.02283.x.
55. Greenbaum SS, Rubin MG. Surgical pearl: the high-energy pulsed carbon dioxide laser for immediate scar resurfacing. *J Am Acad Dermatol*. 1999;40(6, pt 1):988-990.
56. Ozog DM, Moy RL. A randomized split-scar study of intraoperative treatment of surgical wound edges to minimize scarring. *Arch Dermatol*. 2011;147:1108-1110.
57. Khatri KA, Ross V, Grevelink JM, et al. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. *Arch Dermatol*. 1999;135:391-397.
58. Jeong JT, Kye TC. Resurfacing of pitted facial acne scars with a long-pulsed Er:YAG laser. *Dermatol Surg*. 2001;27:107-110.
59. Tanzi EL, Alster TS. Treatment of atrophic facial acne scars with a dual-mode Er:YAG laser. *Dermatol Surg*. 2002;28:551-555.
60. Woo SH, Park JH, Kye YC. Resurfacing of different types of facial acne scar with short-pulsed, variable-pulsed, and dual mode Er:YAG laser. *Dermatol Surg*. 2004;30(4, pt 1):488-493.
61. Tanzi EL, Alster TS. Single-pass carbon dioxide versus multiple-pass Er:YAG laser skin resurfacing: a comparison of postoperative wound healing and side-effect rates. *Dermatol Surg*. 2003;29:80-84.
62. Omranifard M, Rasti M. Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. *J Res Med Sci*. 2007;12:277-281.
63. Alster TS, Lewis AB, Rosenbach A. Laser scar revision: comparison of CO₂ laser vaporization with and without simultaneous pulsed dye laser treatment. *Dermatol Surg*. 1998;24:1299-1302.
64. Manuskiatti W, Fitzpatrick RE, Goldman MP. Treatment of facial skin using combinations of CO₂, Q-switched alexandrite, flashlamp-pumped pulsed dye, and Er:YAG lasers in the same treatment session. *Dermatol Surg*. 2000;26:114-120.
65. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroids, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. *Arch Dermatol*. 2002;138:1149-1155.
66. Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. *Dermatol Surg*. 2006;32:907-915.
67. Profyris C, Tziotzios C, Do Vale I. Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics part I. the molecular basis of scar formation. *J Am Acad Dermatol*. 2012;66:1-10; quiz 11-12.
68. Liu A, Moy RL, Ozog DM. Current methods employed in the prevention and minimization of surgical scars [published online ahead of print September 14, 2011]. *Dermatol Surg*. 2011;37:1740-1746. ■